Paclitaxel Source
Paclitaxel is derived from the bark of the Pacific yew tree (Taxus brevifolia). 1, 2
Natural Origin and Extraction
Paclitaxel is a natural compound originally isolated from the bark of the Pacific yew tree (Taxus brevifolia Nutt.), a medicinal plant that served as the primary source when this chemotherapeutic agent was first discovered. 1, 3
The FDA-approved formulation specifies that paclitaxel is obtained via an extraction process from Taxus X media 'Hicksii', which represents a cultivated hybrid yew species now used for commercial production. 2
Paclitaxel belongs to the class of diterpene taxanes, which are tetracyclic diterpenoid compounds with proven anticancer activity against multiple malignancies including ovarian, breast, and lung cancers. 3, 4
Alternative Production Methods
Natural extraction from Taxus species has proven environmentally unsustainable and economically unfeasible due to the slow growth of yew trees and limited paclitaxel content in the bark. 4
Alternative production methods have been developed, including artificial cultivation of Taxus plants, microbial fermentation using endophytic fungi, semi-synthetic approaches (such as docetaxel derived from the European yew), tissue and cell culture systems, and biosynthetic pathway engineering. 5, 4, 6, 7
Endophytic fungi isolated from Taxus species show potential for paclitaxel production, though current yields and stability remain limited compared to plant-based sources. 5, 7
Suspension culture of Taxus cells represents a promising sustainable alternative, offering controlled production conditions, though further genetic and environmental optimization is required to achieve commercial-scale yields. 7